Intraoperative kit for aunp-tissue grafts
Ended Project Grant Awarded Last action
- Award ID
- R41AR082170
- Recipient
-
G5 Biological Innovations LLC UEI L6D8RSX6HMF6
- Awarding agency
-
National Insititue of Arthritis and Musculoskeletal and Skin Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $740,186
Award facts
- Assistance listing
- 93.846 Arthritis, Musculoskeletal and Skin Diseases Research
- Completion date
- Place of performance
- Missouri, USA
Award details come from USAspending.gov.
Description
- Abstract
- The proposed technology is an intraoperative kit comprised of a liquid solution which will conjugate gold nanoparticles (aunps) to tissue grafts within minutes. Tissue grafts, such as those used in ACL reconstruction surgery, rarely achieve 100% graft assimilation, thereby leading to a host of problems. A potential solution is to modify the grafts in order to enhance integration and reduce inflammation and thus improve clinical outcomes. The innovation of this technology is the development of the intraoperative kit to attach aunps to grafts in surgical suite settings. These grafts can be autografts or commercially available allografts, xenografts, or any other natural materials such as collagen or 3D printed tissues. The specific aims of the project will validate the concept of an intraoperative aunp-tissue conjugation method. Two specific aims will be rigorously pursued, which include 1) optimizing the intraoperative kit method by producing aunp grafts that reduce inflammation while increasing cellular proliferation via in vitro studies and 2) validating the inflammation modulation ability and cellular proliferation of the modified grafts in an ACL reconstruction in vivo model. Currently, there are no commercial technologies that modify biologic grafts in order to promote remodeling and reduce inflammation. The significance of this research is the development of an intraoperative method to modify biological grafts to improve clinical performance. The PI and sub-contract PI have the expertise to pursue the aims of this sttr phase 1 proposal; they have years of experience developing nanomaterial-tissue bionanocomposites and have been involved with several start-up companies.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $95,883 | |
| Amendment | $55,000 | |
| Amendment | $55,000 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $178,101 | |
| Amendment | $178,101 | |
| Original award | $178,101 |
Show all 11
Quick answers
Who received award R41AR082170?
R41AR082170 was awarded to G5 Biological Innovations LLC by National Insititue of Arthritis and Musculoskeletal and Skin Diseases (National Institutes of Health) on September 20, 2022.
How much is award R41AR082170 worth?
$740,186 has been obligated on R41AR082170.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award